Table 3.
Baseline characteristics | |
---|---|
Inclusion and randomisation | |
Screened | 317 |
Randomised | 177 |
Characteristics (%) | |
Ischaemic heart disease | 65 |
Diabetes | 35 |
NYHA classes (%) | |
1 | 38 |
2 | 46 |
3 | 16 |
0 | 0 |
Smoking (%) | |
Currently | 20 |
Previous | 52 |
Never | 28 |
Treatment (%) | |
ACE inhibitor | 64 |
ARB | 30 |
Aspirin | 63 |
β-Blocker | 90 |
Statin | 81 |
Safety | |
Adverse events | 224 |
Serious adverse events | 23 |
ARB, angiotensin 2 receptor blocker.